From the established CSF AD biomarkers, only Aβ42 showed a higher AUC (96.4%) than all CNTNs for the discrimination of AD from bvFTD patients whereas CSF Tau and pTau181 showed AUCs of 87.4% and 67.9. This evidence concerns the gene MAPT and Alzheimer disease.